Cetera Investment Advisers
PYXS icon

Cetera Investment Advisers’s Pyxis Oncology PYXS Stock Holding History

Cetera Investment Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.3K Sell
25,000
-2,260
-8% -$4.32K ﹤0.01% 4713
2026
Q1 		$39.8K Hold
27,260
– – ﹤0.01% 4605
2025
Q4 		$31.3K Sell
27,260
-500
-2% -$1.76K ﹤0.01% 4555
2025
Q3 		$61.6K Sell
27,760
-1,000
-3% -$1.44K ﹤0.01% 4405
2025
Q2 		$31.6K Buy
28,760
+900
+3% +$1.01K ﹤0.01% 4001
2025
Q1 		$27.3K Buy
27,860
+1,000
+4% +$1.33K ﹤0.01% 3897
2024
Q4 		$41.9K Buy
26,860
+1,000
+4% +$2.88K ﹤0.01% 3665
2024
Q3 		$94.9K Sell
25,860
-2,250
-8% -$7.87K ﹤0.01% 3546
2024
Q2 		$93K Sell
28,110
-1,250
-4% -$5.25K ﹤0.01% 3522
2024
Q1 		$125K Buy
29,360
+8,998
+44% +$37.8K ﹤0.01% 3455
2023
Q4 		$36.7K Buy
20,362
+1,102
+6% +$1.89K ﹤0.01% 2178
2023
Q3 		$38.3K Buy
19,260
+1,000
+5% +$2.32K ﹤0.01% 2138
2023
Q2 		$46.7K Buy
+18,260
New +$57.9K ﹤0.01% 2126

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's PYXS Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Pyxis Oncology (PYXS) stake by 8.3% in Q2 2026, selling an estimated $4.32K and leaving 25,000 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4713.

Cetera Investment Advisers first reported a position in PYXS in Q2 2023 and has held it in 13 quarters since. The position peaked at $125K in Q1 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Cetera Investment Advisers held 25,000 shares of Pyxis Oncology worth $75.3K as of Q2 2026.
  • Cetera Investment Advisers sold 2,260 Pyxis Oncology shares in Q2 2026, an estimated $4.32K.
  • Pyxis Oncology made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4713 holding.
  • Cetera Investment Advisers first reported a position in Pyxis Oncology in Q2 2023 and has held it in 13 quarters since.
  • Cetera Investment Advisers's Pyxis Oncology position peaked at $125K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.